AMLSG

Publications

• Publications 2025
• Publications 2024
• Publications 2023
• Publications 2022
• Publications 2021
• older Publications

2025

• Disease cha­rac­te­ristics and out­co­mes of acute mye­loid leuke­mia in germ­line RUNX1 defi­ci­ency (Fami­lial Pla­te­let Dis­or­der with asso­cia­ted Mye­loid Mali­gnancy). Ernst MPT, Vers­luis J, Valk PJM, Bie­rings M, Tamminga RYJ, Hoo­imei­jer LH, Döh­ner K, Gre­sele P, Tawana K, Lan­ge­mei­jer SMC, Van der Reij­den BA, Pod­gor­nik H, Sever M, Tvedt THA, Vul­liamy T, Fitz­gib­bon J, Dokal I, Balia­kas P, Bas­tida JM, Pohl­kamp C, Hafer­lach T, Lar­cher L, Soulier J, Schutgens REG, Fre­son K, Duployez N, Löwen­berg B, Eric­son K, Cam­menga J, Rip­per­ger T, Raaij­ma­kers MHGP. Hemas­phere. 2025 Jan 16;9(1):e70057. doi: 10.1002/hem3.70057. eColl­ec­tion 2025 Jan.
• Impact of myelodysplasia-​related and addi­tio­nal gene muta­ti­ons in inten­si­vely trea­ted pati­ents with NPM1-​mutated AML. Coc­ci­ardi S, Saa­dati M, Weiß N, Späth D, Kapp-​Schwoerer S, Schnei­der I, Meid A, Gaid­zik VI, Skam­braks S, Fied­ler W, Kühn MWM, Ger­ming U, Mayer KT, Lüb­bert M, Papaem­ma­nuil E, Thol F, Heu­ser M, Gan­ser A, Bul­lin­ger L, Ben­ner A, Döh­ner H, Döh­ner K. Hemas­phere. 2025 Jan 15;9(1):e70060. doi: 10.1002/hem3.70060. eColl­ec­tion 2025 Jan.
• Acute Pro­mye­lo­cy­tic Leuke­mia: Long-​Term Out­co­mes from the HARM­ONY Pro­ject. Voso MT, Guar­nera L, Leh­mann S, Döh­ner K, Döh­ner H, Platz­be­cker U, Rus­sell NH, Dil­lon RJ, Tho­mas I, Ossen­kop­pele GJ, Hafer­lach T, Vignetti M, La Sala E, Picioc­chi A, Fazi P, Vil­la­verde Ramiro Á, Tur Giménez L, Gurn­ari C, Bul­lin­ger L, Her­nan­dez JM. Blood. 2025 Jan 9;145(2):234-243.
• Out­co­mes with inten­sive treat­ment for acute mye­loid leuke­mia: an ana­ly­sis of two deca­des of data from the HARM­ONY Alli­ance. Sobas MA, Turki AT, Ramiro AV, Sánchez AH, Elice­gui JM, González T, Mel­chor RA, Abáigar M, Tur L, Dall'Olio D, Sträng E, Tet­tero JM, Cas­tel­lani G, Ben­ner A, Döh­ner K, Thiede C, Met­ze­ler KH, Hafer­lach T, Damm F, Ayala R, Martínez-​López J, Mills KI, Sierra J, Leh­mann S, Porta MGD, Mayer J, Rein­hardt D, Medina RV, Schulze-​Rath R, Bar­bus M, Hernández-​Rivas JM, Huntly BJP, Ossen­kop­pele G, Döh­ner H, Bul­lin­ger L. Hae­ma­to­lo­gica. 2024 Nov 7. doi: 10.3324/hae­ma­tol.2024.285805. Online ahead of print.
• Impact of TP53 Muta­tion Sta­tus in Elderly AML Pati­ents When Adding All-​Trans Reti­noic Acid or Val­proic Acid to Deci­ta­bine. Bres­ser H, Schmoor C, Gris­hina O, Pfei­fer D, Tho­mas J, Reh­man UU, Cry­sandt M, Jost E, Thol F, Heu­ser M, Götze KS, Schlenk RF, Salih HR, Schit­ten­helm MM, Heil G, Schwae­nen C, Müller-​Tidow C, Brug­ger W, Künd­gen A, de Wit M, Gia­gouni­dis A, Scholl S, Neu­bauer A, Krau­ter J, Bug G, May AM, Wäsch R, Duys­ter J, Döh­ner K, Gan­ser A, Döh­ner H, Hack­an­son B, Becker H, Lüb­bert M. Eur J Hae­ma­tol. 2025 Feb;114(2):231-237. Epub 2024 Oct 13.

2024

• Con­ti­nued deci­ta­bine/all-​trans reti­noic acid treat­ment: exten­ded com­plete remis­sion in an elderly AML pati­ent with multi-​hit TP53 lesi­ons and complex-​monosomal karyo­type. Tho­mas J, Reh­man UU, Bres­ser H, Gris­hina O, Pfei­fer D, Sol­lier E, Döh­ner K, Plass C, Becker H, Schmoor C, de Wit M, Lüb­bert M. Clin Epi­ge­ne­tics. 2024 Sep 11;16(1):126.
• Mea­sura­ble Resi­dual Disease Moni­to­ring in AML With FLT3-ITD Trea­ted With Inten­sive Che­mo­the­rapy Plus Mido­stau­rin. Rücker FG, Bul­lin­ger L, Coc­ci­ardi S, Skam­braks S, Luck TJ, Weber D, Krzy­kalla J, Pozek E, Schnei­der IJ, Cor­ba­cio­glu A, Gaid­zik VI,Meid A Dr, Aicher S, Ste­gel­mann F, Schrade A,Theis F, Fied­ler W, Salih HR, Wulf GG, Sal­wen­der HJ, Schroe­der T, Götze KS, Kühn MWM, Lüb­bert M, Schlenk RF, Ben­ner A, Thol FR, Heu­ser M, Gan­ser A, Döh­ner H, Döh­ner K. Blood Adv. 2024 Dec 10;8(23):6067-6080.
• Out­co­mes of Haplo­iden­ti­cal Trans­plants with PT-CY ver­sus 10/10 MUD Trans­plants with ATG in Ger­many. Ars­lan A, Labuhn S, Sala E, Ring­hof­fer M, Sche­te­lig J, Schroe­der T, Bug G, Franke GN, Stell­jes M, Dre­ger P, Zei­ser R, Tesch­ner D, Bethge WA, Eder M, Edin­ger M, Amann EM, Neu­chel C, Schmid-​Möglich A, Schmel­ler S, Bey­ers­mann J, Schre­zen­meier H, Myti­li­neos J, Krö­ger N, Fuerst D. Blood Adv. 2024 Dec 10;8(23):6104-6113.
• Geno­mic cha­rac­te­riza­tion of AML with aberra­ti­ons of chro­mo­some 7: a mul­ti­na­tio­nal cohort of 519 pati­ents. Halik A, Til­g­ner M, Silva P, Estrada N, Alt­was­ser R, Jahn E, Heu­ser M, Hou HA, Prat­co­rona M, Hills RK, Met­ze­ler KH, Fen­warth L, Dol­nik A, Terre C, Kopp K, Blau O, Szyska M, Chris­ten F, Krönke J, Vas­seur L, Löwen­berg B, Esteve J, Valk PJM, Duch­mann M, Chou WC, Linch DC, Döh­ner H, Gale RE, Döh­ner K, Bul­lin­ger L, Yoshida K, Damm F. J Hema­tol Oncol. 2024 Aug 19;17(1):70.
• Gene­tic risk clas­si­fi­ca­tion for adults with AML recei­ving less-​intensive the­ra­pies: the 2024 ELN recom­men­da­ti­ons. Döh­ner H, DiNardo CD, Wei AH, Löwen­berg B, Appel­baum F, Crad­dock C, Dom­bret H, Ebert BL, Fen­aux P, God­ley LA, Has­serjian RP, Lar­son RA, Levine RL, Miya­zaki Y, Nie­der­wie­ser D, Ossen­kop­pele GJ, Röl­lig C, Sierra J, Stein EM, Tall­man MS, Tien HF, Wang J, Wierz­bowska A. Blood. 2024 Nov 21;144(21):2169-2173.
• Gene­tic Risk Stra­ti­fi­ca­tion and Out­co­mes Among Treatment-​Naive Pati­ents With AML Trea­ted With Vene­toclax and Aza­ci­ti­dine. Döh­ner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pul­lar­kat V, Thir­man MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Pot­luri J, Dail M, Chyla B, Pol­lyea DA. Blood. 2024 Nov 21;144(21):2211-2222.
• Safety and tole­ra­bi­lity of AMG 330 in adults with relap­sed/refrac­tory AML: a phase 1a dose-​escalation study. Ravandi F, Sub­klewe M, Wal­ter RB, Vachhani P, Ossen­kop­pele G, Bueck­lein V, Döh­ner H, Jongen-​Lavrencic M, Bal­dus CD, Frans­e­cky L, Par­dee TS, Kant­ar­jian H, Yen PK, Mukun­dan L, Pan­war B, Yago MR, Agar­wal S, Khal­doya­nidi SK, Stein A. Leuk Lym­phoma. 2024 Sep;65(9):1281-1291. Epub 2024 May 7.
• Long-​term follow-​up of VIALE-​A: Venetoclax and azacitidine in chemotherapy-​ineligible untreated acute myeloid leukemia. Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Döhner H, Récher C, Fiedler W, Yamamoto K, Wang J, Yoon SS, Wolach O, Yeh SP, Leber B, Esteve J, Mayer J, Porkka K, Illés Á, Lemoli RM, Turgut M, Ku G, Miller C, Zhou Y, Zhang M, Chyla B, Potluri J, DiNardo CD. Am J Hematol. 2024 Apr;99(4):615-624. Epub 2024 Feb 11.
• Gua­de­ci­ta­bine vs TC in relap­sed/refrac­tory AML after inten­sive che­mo­the­rapy: ran­do­mi­zed phase 3 ASTRAL-​2 trial. Roboz GJ, Sanz GF, Grif­fiths EA, Yee KWL, Kant­ar­jian HM, Récher C, Byrne MT, Pat­kowska E, Kim HJ, Tho­mas X, Moors I, Stock W, Illes A, Fen­aux P, Miya­zaki Y, Yamauchi T, O'Con­nell C, Hao Y, Keer HN, Azab M, Döh­ner H. Blood Adv. 2024 Apr 23;8(8):2020-2029.
• How I treat refrac­tory and relap­sed acute mye­loid leuke­mia. Thol FR, Döh­ner H, Gan­ser A. Blood. 2024 Jan 4;143(1):11-20.
• Sur­vi­val out­co­mes in pati­ents with acute mye­loid leu­ka­e­mia who recei­ved sub­se­quent the­rapy for relapse in QUA­ZAR AML-001. Ravandi F, Döh­ner H, Wei AH, Mon­te­si­nos P, Pfeil­stö­cker M, Papa­yan­nidis C, Lai Y, Wang K, See WL, de Mene­zes DL, Petrlik E, Pre­bet T, Roboz GJ. Br J Hae­ma­tol. 2024 Mar;204(3):877-886. Epub 2023 Nov 12.
• Low-​dose aza­ci­ti­dine, pio­g­li­ta­zone and all-​trans reti­noic acid is safe in pati­ents aged ≥ 60 years with acute mye­loid leuke­mia refrac­tory to stan­dard induc­tion che­mo­the­rapy (AMLSG 26-16/AML-​ViVA): results of the safety run-​in phase. Heu­do­bler D, Luke F, Hahn J, Grube M, Schlos­ser P, Kre­mers S, Sud­hoff T, Wes­ter­mann J, Hutter-​Kronke ML, Schlenk RF, Weber D, Paschka P, Zeman F, Doh­ner H, Herr W, Reichle A, Tho­mas S. Hae­ma­to­lo­gica. 2024 Apr 1;109(4):1274-1278.

2023

• AML with com­plex karyo­type: extreme geno­mic com­ple­xity revea­led by com­bi­ned long-​read sequen­cing and Hi-C tech­no­logy. Kle­ver MK, Sträng E, Het­zel S, Jung­nitsch J, Dol­nik A, Schöpf­lin R, Schre­zen­meier JF, Schick F, Blau O, Wes­ter­mann J, Rücker FG, Xia Z, Döh­ner K, Schre­zen­meier H, Spiel­mann M, Meiss­ner A, Melo US, Mund­los S, Bul­lin­ger L. Blood Adv. 2023 Nov 14;7(21):6520-6531.
• Cli­ni­cal impact of the geno­mic land­s­cape and leu­ke­mo­ge­nic tra­jec­to­ries in non-​intensively trea­ted elderly acute mye­loid leuke­mia pati­ents. Jahn E, Saa­dati M, Fen­aux P, Gobbi M, Roboz GJ, Bul­lin­ger L, Lutsik P, Rie­del A, Plass C, Jahn N, Wal­ter C, Holz­mann K, Hao Y, Naim S, Schreck N, Krzy­kalla J, Ben­ner A, Keer HN, Azab M, Döh­ner K, Döh­ner H. Leuke­mia. 2023 Nov;37(11):2187-2196. Epub 2023 Aug 17.
• AML con­so­li­da­tion the­rapy: timing mat­ters. Rei­mann AM, Schalk E, Jost F, Mou­gia­ka­kos D, Weber D, Döh­ner H, Récher C, Dumas PY, Ditz­haus M, Fischer T, Sager S. J Can­cer Res Clin Oncol. 2023 Nov;149(15):13811-13821. Epub 2023 Aug 3.
• Menin inhi­bi­tor zifto­me­nib (KO-539) syn­er­gi­zes with drugs tar­ge­ting chro­ma­tin regu­la­tion or apo­pto­sis and sen­si­ti­zes acute mye­loid leuke­mia with MLL rear­ran­ge­ment or NPM1 muta­tion to vene­toclax. Rausch J, Dzama MM, Dol­gikh N, Stil­ler HL, Bohl SR, Lahr­mann C, Kunz K, Kess­ler L, Ech­chan­naoui H, Chen CW, Kind­ler T, Döh­ner K, Bur­rows F, Theo­bald M, Sasca D, Kühn MWM. Hae­ma­to­lo­gica. 2023 Oct 1;108(10):2837-2843.
• Sur­vi­val out­co­mes with oral aza­ci­ti­dine main­ten­ance in pati­ents with acute mye­loid leuke­mia in remis­sion by receipt of initial che­mo­the­rapy: sub­group ana­ly­ses from the phase 3 QUA­ZAR AML-001 trial. Wei AH, Roboz GJ, Dom­bret H, Doh­ner H, Schuh AC, Mon­te­si­nos P, Sel­les­lag D, Bon­da­renko SN, Pre­bet T, Lai Y, Ski­kne B, Beach CL, Ravandi F. Hae­ma­to­lo­gica. 2023 Oct 1;108(10):2820-2825.
• Ran­do­mi­zed phase-​III study of low-​dose cyt­ara­bine and eto­po­side + /- all-​trans reti­noic acid in older unfit pati­ents with NPM1-​mutated acute mye­loid leuke­mia. Schlenk RF, Weber D, Krzy­kalla J, Kind­ler T, Wulf G, Her­ten­stein B, Salih HR, Süd­hoff T, Krau­ter J, Mar­tens U, Wes­sen­dorf S, Runde V, Tisch­ler HJ, Bentz M, Kol­ler E, Heu­ser M, Thol F, Ben­ner A, Gan­ser A, Döh­ner K, Döh­ner H. Sci Rep. 2023 Sep 8;13(1):14809.
• All sys­tems are not GO: ongo­ing chal­lenges in inter­pre­ting gem­tu­zu­mab ozoga­micin cli­ni­cal trial results - Authors' reply. Döh­ner H, Ben­ner A, Gan­ser A. Lan­cet Hae­ma­tol. 2023 Sep;10(9):e707.
• Gua­de­ci­ta­bine vs treat­ment choice in newly dia­gno­sed acute mye­loid leuke­mia: a glo­bal phase 3 ran­do­mi­zed study. Fen­aux P, Gobbi M, Kropf P, Issa JJ, Roboz GJ, Mayer J, Krau­ter J, Robak T, Kant­ar­jian HM, Novak J, Jedrze­jczak WW, Tho­mas X, Ojeda-​Uribe M, Miya­zaki Y, Min YH, Yeh SP, Brand­wein JM, Gercheva-​Kyuchukova LT, Deme­ter J, Grif­fiths EA, Yee KWL, Döh­ner K, Hao Y, Keer HN, Azab M, Döh­ner H. Blood Adv. 2023 Sep 12;7(17):5027-5037.
• Phase I study eva­lua­ting the Fc-​optimized FLT3 anti­body FLY­SYN in AML pati­ents with mea­sura­ble resi­dual disease. Heit­mann JS, Schlenk RF, Dör­fel D, Kay­ser S, Döh­ner K, Heu­ser M, Thol F, Kapp-​Schwoerer S, Lab­renz J, Edel­mann D, Märk­lin M, Vogel W, Bethge W, Walz JS, Große-​Hovest L, Stei­ner M, Jung G, Salih HR. J Hema­tol Oncol. 2023 Aug 17;16(1):96.
• Acti­vity of deci­ta­bine com­bi­ned with all-​trans reti­noic acid in oli­go­blastic AML: Results from a ran­do­mi­zed 2x2 phase II trial (DECI­DER). Rum­melt C, Gris­hina O, Schmoor C, Cry­sandt M, Heu­ser M, Götze KS, Schlenk RF, Döh­ner K, Salih HR, Heil G, Müller-​Tidow C, Brug­ger W, Künd­gen A, De Wit M, Gia­gouni­dis A, Scholl S, Neu­bauer A, Krau­ter J, Bug G, Al-​Ali HK, Wäsch R, Becker H, May AM, Duys­ter J, Hack­an­son B, Gan­ser A, Döh­ner H, Lüb­bert M. Hae­ma­to­lo­gica. 2023 Aug 1;108(8):2244-2248.
• Inten­sive che­mo­the­rapy with or wit­hout gem­tu­zu­mab ozoga­micin in pati­ents with NPM1-​mutated acute mye­loid leu­ka­e­mia (AMLSG 09-09): a ran­do­mi­sed, phase 3 trial. Döh­ner H, Weber D, Krzy­kalla J, Fied­ler W, Kühn MWM, Schroe­der T, Mayer K, Lüb­bert M, Wat­tad M, Götze K, Frans­e­cky L, Kol­ler E, Wulf G, Schlei­cher J, Ring­hof­fer M, Greil R, Her­ten­stein B, Krau­ter J, Mar­tens UM, Nach­baur D, Samra MA, Machherndl-​Spandl S, Basara N, Leis C, Schrade A, Kapp-​Schwoerer S,Coc­ci­ardi S, Bul­lin­ger L, Thol F, Heu­ser M, Paschka P, Gaid­zik VI, Saa­dati S, Ben­ner A, Schlenk, RF Döh­ner K, Gan­ser A; on behalf of the German-​Austrian AML Study Group (AMLSG). Lan­cet Hae­ma­tol. 2023 Jul;10(7):e495-e509. Epub 2023 May 12.
• The Inter­na­tio­nal Con­sen­sus Clas­si­fi­ca­tion of Acute Leuke­mias of Ambi­guous Lineage. Wein­berg OK, Arber DA, Döh­ner H, Mul­lig­han CG, Orgel E, Por­wit A, Stone RM, Boro­witz MJ. Blood. 2023 May 4;141(18):2275-2277.
• Pal­bo­ci­c­lib in Acute Leuke­mias With KMT2A-​rearrangement: Results of AMLSG 23-14 Trial. Gaid­zik VI, Paschka P, Schlenk RF, Weber D, Fröh­ling S, Krä­mer A, Wäsch R, Wes­ter­mann J, Mayer K, de Wit M, Fied­ler W, Ben­ner A, Heu­ser M, Thol F, Döh­ner K, Gan­ser A, Döh­ner H. Hemas­phere. 2023 Apr 21;7(5):e877.
• Long-​term sur­vi­val with oral aza­ci­ti­dine for pati­ents with acute mye­loid leuke­mia in first remis­sion after che­mo­the­rapy: updated results from the ran­do­mi­zed, placebo-​controlled, phase 3 QUA­ZAR AML-001 trial. Wei AH, Döh­ner H, Sayar H, Ravandi F, Mon­te­si­nos P, Dom­bret H, Sel­les­lag D, Porkka K, Jang JH, Ski­kne B, Beach CL, Pre­bet T, Zhang G, Risueño A, Ugi­dos M, See WL, Mene­zes D, Roboz GJ. Am J Hema­tol. 2023 Apr;98(4):E84-E87. Epub 2023 Feb 6.
• Ena­si­de­nib vs con­ven­tio­nal care in older pati­ents with late-​stage mutant-​IDH2 relap­sed/refrac­tory AML: a ran­do­mi­zed phase 3 trial. de Bot­ton S, Mon­te­si­nos P, Schuh AC, Papa­yan­nidis C, Vyas P, Wei AH, Ommen H, Semoch­kin S, Kim HJ, Lar­son RA, Kopriv­ni­kar J, Frank­furt O, Thol F, Chro­mik J, Byrne J, Pigneux A, Tho­mas X, Sal­a­mero O, Vid­ria­les MB, Doro­nin V, Döh­ner H, Fathi AT, Laille E, Yu X, Hasan M, Martin-​Regueira P, DiNardo CD. Blood. 2023 Jan 12;141(2):156-167.
• Inter­na­tio­nal Con­sen­sus Clas­si­fi­ca­tion for Mye­loid Neo­plasms At-​​A-Glance. Orazi A, Has­serjian RP, Caz­zola M, Döh­ner H, Tef­feri A, Arber DA. Am J Hema­tol. 2023 Jan;98(1):6-10. Epub 2022 Nov 8.

2022

• First-​in-human study of WT1 recom­bi­nant pro­tein vac­ci­na­tion in elderly pati­ents with AML in remis­sion: a single-​center expe­ri­ence. Kreut­mair S, Pfei­fer D, Water­house M, Takács F, Graes­sel L, Döh­ner K, Duys­ter J, Illert AL, Frey AV, Schmitt M, Lüb­bert M. Can­cer Immu­nol Immu­n­o­ther. 2022 Dec;71(12):2913-2928. Epub 2022 Apr 27.
• Geno­mic Pro­fi­ling for Cli­ni­cal Decision Making in Mye­loid Neo­plasms and Acute Leuke­mia. Dun­ca­vage EJ, Bagg A, Has­serjian RP, DiNardo CD, God­ley LA, Iaco­bucci I, Jais­wal S, Mal­co­vati L, Van­nuc­chi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Ber­li­ner N, Boro­witz MJ, Bran­ford S, Brown AL, Cargo CA, Döh­ner H, Falini B, Garcia-​Manero G, Hafer­lach T, Hellström-​Lindberg E, Kim AS, Klco JM, Kom­rokji RS, Loh ML, Log­havi S, Mul­lig­han CG, Ogawa S, Tef­feri A, Papaem­ma­nuil E, Rei­ter A, Ross DM, Savona MR, Shi­ma­mura A, Skoda RC, Sole F, Stone RM, Orazi A, Wal­ter MJ, Wu D, Ebert BL, Caz­zola M. Blood. 2022 Nov 24;140(21):2228-2247.
• Response to "The WHO clas­si­fi­ca­tion of hae­ma­t­o­lym­phoid tumours" (Edi­to­rial). Swerd­low SH, Campo E, Arber DA, Caz­zola M, Cook JR, Döh­ner H, Drey­ling M, Has­serjian RP, Jaffe ES, Orazi A, Quintanilla-​Martinez L, Scott DW, Tef­feri A, Win­ter JN, Zel­e­netz AD. Leuke­mia. 2022 Nov;36(11):2748-2749. Epub 2022 Aug 27.
• Pro­gno­stic impact of NPM1 and FLT3 muta­ti­ons in pati­ents with AML in first remis­sion trea­ted with oral aza­ci­ti­dine. Döh­ner H, Wei AH, Roboz GJ, Mon­te­si­nos P, Thol FR, Ravandi F, Dom­bret H, Porkka K, Sandhu I, Ski­kne BS, See WL, Ugi­dos M, Risueño A, Chan ET, Tha­kurta A, Beach CL, Lopes de Mene­zes D. Blood. 2022 Oct 13;140(15):1674-1685.
• Asso­cia­tion of FLT3-ITD length with over­all sur­vi­val in acute mye­loid leuke­mia: a sys­te­ma­tic review and meta-​analysis. Polak TB, Van Ros­ma­len J, Dir­ven S, Her­zig JK, Cloos J, Mes­hin­chi S, Döh­ner K, Jans­sen JJWM, Cuc­chi DGJ. Hae­ma­to­lo­gica. 2022 Oct 1;107(10):2506-2510.
• Broad geno­mic workup inclu­ding opti­cal genome map­ping unco­vers a DDX3X: MLLT10 gene fusion in acute mye­loid leuke­mia. Nilius-​Eliliwi V, Tem­brink M, Ger­ding WM, Lub­ie­niecki KP, Lub­ie­nie­cka JM, Kan­kel S, Liehr T, Mika T, Dimo­pou­los F, Döh­ner K, Schro­ers R, Nguyen HHP, Van­gala DB. Front Oncol. 2022 Sep 9;12:959243. doi: 10.3389/fonc.2022.959243. eColl­ec­tion 2022.
• Geno­mic land­s­cape of pati­ents with FLT3-​mutated acute mye­loid leuke­mia (AML) trea­ted within the CALGB 10603/RATIFY trial. Jahn N, Jahn E, Saa­dati M, Bul­lin­ger L, Lar­son RA, Ottone T, Ama­dori S, Prior TW, Brand­wein JM, Appel­baum FR, Medei­ros BC, Tall­man MS, Ehnin­ger G, Heu­ser M, Gan­ser A, Pal­laud C, Gath­mann I, Krzy­kalla J, Ben­ner A, Bloom­field CD, Thiede C, Stone RM, Döh­ner H, Döh­ner K. Leuke­mia. 2022 Sep;36(9):2218-2227. Epub 2022 Aug 3.
• Dia­gno­sis and Manage­ment of AML in Adults: 2022 ELN Recom­men­da­ti­ons from an Inter­na­tio­nal Expert Panel. Döh­ner H, Wei AH, Appel­baum FR, Crad­dock C, DiNardo CD, Dom­bret H, Ebert BL, Fen­aux P, God­ley LA, Has­serjian RP, Lar­son RA, Levine RL, Miya­zaki Y, Nie­der­wie­ser D, Ossen­kop­pele GJ, Röl­lig C, Sierra J, Stein EM, Tall­man MS, Tien HF, Wang J, Wierz­bowska A, Löwen­berg B. Blood. 2022 Sep 22;140(12):1345-1377.
• Enhan­ced sti­mu­la­tion of antigen-​specific immune respon­ses against nucleo­phos­min 1 muta­ted acute mye­loid leu­ka­e­mia by an anti-​programmed death 1 anti­body.  Grei­ner J, Goetz M, Schuler PJ, Bulach C, Hof­mann S, Schre­zen­meier H, Dӧhner H, Schnei­der V, Guinn BA. Br J Hae­ma­tol. 2022 Sep;198(5):866-874. Epub 2022 Jul 7.
• Inter­na­tio­nal Con­sen­sus Clas­si­fi­ca­tion of Mye­loid Neo­plasms and Acute Leuke­mia: Inte­gra­ting Mor­pho­lo­gi­cal, Cli­ni­cal, and Geno­mic Data. Arber DA, Orazi A, Has­serjian RP, Boro­witz MJ, Calvo KR, Kvas­ni­cka HM, Wang SA, Bagg A, Bar­bui T, Bran­ford S, Bueso-​Ramos CE, Cor­tes J, Dal Cin P, DiNardo CD, Dom­bret H, Dun­ca­vage EJ, Ebert BL, Estey E, Fac­chetti F, Fou­car K, Gangat N, Gia­nelli U, God­ley LA, Goek­bu­get N, Got­lib JR, Hellström-​Lindberg E, Hobbs G, Hoff­man R, Jabbour EJ, Kilad­jian JJ, Lar­son RA, Le Beau MM, Loh ML, Löwen­berg B, Mac­in­tyre EA, Mal­co­vati L, Mul­lig­han CG, Nie­meyer CM, Ode­nike O, Ogawa S, Orfao A, Papaem­ma­nuil E, Pas­sa­monti F, Porkka K, Pui CH, Radich JP, Rei­ter A, Roz­man M, Rude­lius M, Savona MR, Schif­fer C, Schmitt-​Graeff A, Shi­ma­mura A, Sierra J, Stock W, Stone RM, Tall­man MS, Thiele J, Tien HF, Tzan­kov A, Van­nuc­chi AM, Vyas P, Wei AH, Wein­berg OK, Wierz­bowska A, Caz­zola M, Döh­ner H, Tef­feri A.Blood. 2022 Sep 15;140(11):1200-1228.
• Mido­stau­rin plus inten­sive che­mo­the­rapy for youn­ger and older pati­ents with AML and FLT3 inter­nal tan­dem dupli­ca­ti­ons. Döh­ner H, Weber D, Krzy­kalla J, Fied­ler W, Wulf GG, Salih HR, Lüb­bert M, Kühn M, Schroe­der T, Sal­wen­der H, Götze KS, Wes­ter­mann J, Frans­e­cky L, Mayer K, Her­ten­stein B, Ring­hof­fer M, Tisch­ler HJ, Machherndl-​Spandl S, Schrade A, Paschka P, Gaid­zik VI, Theis F, Thol FR, Heu­ser M, Schlenk RF, Bul­lin­ger L, Saa­dati M, Ben­ner A, Lar­son RA, Stone RM, Döh­ner K, Gan­ser A. Blood Adv. 2022 Sep 27;6(18):5345-5355.
• Uni­fied clas­si­fi­ca­tion and risk-​stratification in Acute Mye­loid Leuke­mia. Tazi Y, Arango-​Ossa JE, Zhou Y, Ber­nard E, Tho­mas I, Gil­kes A, Free­man S, Pra­dat Y, John­son SJ, Hills R, Dil­lon R, Levine MF, Leon­ga­morn­lert D, But­ler A, Gan­ser A, Bul­lin­ger L, Döh­ner K, Ott­mann O, Adams R, Döh­ner H, Camp­bell PJ, Bur­nett AK, Den­nis M, Rus­sell NH, Dev­lin SM, Huntly BJP, Papaem­ma­nuil E. Nat Com­mun. 2022 Aug 8;13(1):4622.
• Pro­spec­tive com­pa­ri­son of out­co­mes with aza­ci­ti­dine and deci­ta­bine in AML pati­ents ine­li­gi­ble for inten­sive che­mo­the­rapy. Zei­dan AM, Fen­aux P, Gobbi M, Mayer J, Roboz GJ, Krau­ter J, Robak T, Kant­ar­jian HM, Novak J, Jedrze­jczak WW, Tho­mas X, Ojeda-​Uribe M, Miya­zaki Y, Min YH, Yeh SP, Brand­wein JM, Ger­cheva LT, Deme­ter J, Grif­fiths EA, Yee KW, Issa JJ, Bewers­dorf JPP, Keer HN, Hao Y, Azab M, Döh­ner H. Blood 2022 Jul 21;140(3):285-289. No abs­tract availa­ble.
• Ivo­si­de­nib and Aza­ci­ti­dine in IDH1-​Mutated AML. Reply. Mon­te­si­nos P, de Bot­ton S, Döh­ner H. N Engl J Med. 2022;386(26):2536-2537.
• Clas­si­fi­ca­tion of mye­loid neo­plasms/acute leuke­mia: glo­bal per­spec­ti­ves and the Inter­na­tio­nal Con­sen­sus Clas­si­fi­ca­tion (ICC) approach. Arber DA, Has­serjian RP, Orazi A, Mathews V, Roberts AW, Schif­fer CA, Roug AS, Caz­zola M, Döh­ner H, Tef­feri A.Am J Hema­tol. 2022 May;97(5):514-518.
• Ivo­si­de­nib and Aza­ci­ti­dine in IDH1-​Mutated Acute Mye­loid Leuke­mia. Mon­te­si­nos P, Recher C, Vives S, Zar­zy­cka E, Wang J, Ber­tani G, Heu­ser M, Calado RT, Schuh AC, Yeh SP, Dai­gle SR, Hui J, Pan­dya SS, Gia­no­lio DA, de Bot­ton S, Döh­ner H. N Engl J Med. 2022 Apr 21;386(16):1519-1531.
• Oral Aza­ci­ti­dine (CC-486) for the Treat­ment of Mye­loid Mali­gnan­cies. Garcia-​Manero G, Döh­ner H, Wei AH, La Torre I, Ski­kne B, Beach CL, San­tini V. Clin Lym­phoma Mye­loma Leuk. 2022 Apr;22(4):236-250. Review.
• Oral aza­ci­ti­dine pro­longs sur­vi­val of pati­ents with AML in remis­sion inde­pen­dent of mea­sura­ble resi­dual disease sta­tus. Roboz GJ, Ravandi F, Wei AH, Dom­bret H, Thol F, Voso MT, Schuh AC, Porkka K, La Torre I, Ski­kne BS, Zhong J, Beach CL, Risueño A, Lopes de Mene­zes D, Ossen­kop­pele GJ, Döh­ner H. Blood. 2022 Apr 7;139(14):2145-2155.
• Mea­sura­ble resi­dual disease response and pro­gno­sis in treatment-​naïve acute mye­loid leuke­mia with vene­toclax and aza­ci­ti­dine. Pratz KW, Jonas BA, Pul­lar­kat V, Recher C, Schuh AC, Thir­man MJ, Gar­cia JS, DiNardo CD, Vor­o­byev V, Frac­chiolla NS, Yeh SP, Jang JH, Ozcan M, Yama­moto K, Illes A, Zhou Y, Dail M, Chyla B, Pot­luri J, Döh­ner H. J Clin Oncol. 2022 Mar 10;40(8):855-865.
• Mole­cu­lar land­s­cape and pro­gno­stic impact of FLT3-ITD inser­tion site in acute mye­loid leuke­mia: RATIFY study results. Rücker FG, Du L, Luck TJ, Ben­ner A, Krzy­kalla J, Gath­mann I, Voso MT, Ama­dori S, Prior TW, Brand­wein JM, Appel­baum FR, Medei­ros BC, Tall­man MS, Savoie L, Sierra J, Pal­laud C, Sanz MA, Jan­sen JH, Nie­der­wie­ser D, Fischer T, Ehnin­ger G, Heu­ser M, Gan­ser A, Bul­lin­ger L, Lar­son RA, Bloom­field CD, Stone RM, Döh­ner H, Thiede C, Döh­ner K.Leuke­mia. 2022 Jan;36(1):90-99.

2021

• 2021 Update Mea­sura­ble Resi­dual Disease in Acute Mye­loid Leuke­mia: European Leuke­mia­Net Work­ing Party Con­sen­sus Docu­ment. Czyz A, Denys B, Dil­lon R, Feuring-​Buske M, Guz­man ML, Hafer­lach T, Han L, Her­zig JK, Jor­gen­sen JL, Kern W, Kono­pleva MY, Lacombe F, Libura M, Majchrzak A, Mau­r­illo L, Ofran Y, Philippé J, Plesa A, Preud­homme C, Ravandi F, Rou­mier C, Sub­klewe M, Thol F, van de Loos­d­recht AA, van der Reij­den BA, Ven­ditti A, Wierz­bowska A, Valk PJM, Wood BL, Wal­ter RB, Thiede C, Döh­ner K, Roboz GJ, Cloos J. Blood. 2021 Dec 30;138(26):2753-2767.
• Oral aza­ci­ti­dine pre­ser­ves favorable level of fati­gue and health-​related qua­lity of life for pati­ents with acute mye­loid leuke­mia in remis­sion: results from the phase 3, pla­ce­bo­con­trol­led QUA­ZAR AML-001 trial. Roboz GJ, Doh­ner H, Pocock C, Dom­bret H, Ravandi F, Jang JH, Sel­les­lag D, Mayer J, Mar­tens UM, Lies­veld J, Ber­nal T, Wang MC, Yu P, Shi L, Guo S, La Torre I, Ski­kne B, Dong Q, Bra­ver­man J, Nehme SA, Beach CL, Wei AH. Hae­ma­to­lo­gica. 2021 Dec 1;106(12):3240-3244.
• Clus­ter of dif­fe­ren­tia­tion 33 sin­gle nucleo­tide poly­mor­phism rs12459419 is a pre­dic­tive fac­tor in pati­ents with nucleo­phos­min1 muta­ted acute mye­loid leuke­mia recei­ving gem­tu­zu­mab ozoga­micin. Teich K, Krzy­kalla J, Kapp-​Schwoerer S, Gaid­zik VI, Schlenk RF, Paschka P, Weber D, Fied­ler W, Kühn MWM, Schroe­der T, Mayer K, Lüb­bert M, Rama­ch­andran D, Ben­ner A, Gan­ser A, Döh­ner H, Heu­ser M, Döh­ner K, Thol F. Hae­ma­to­lo­gica. 2021 Nov 1;106(11):2986-2989.
• Ena­si­de­nib plus aza­ci­ti­dine ver­sus aza­ci­ti­dine alone in pati­ents with newly dia­gno­sed, mutant-​IDH2 acute mye­loid leu­ka­e­mia (AG221-AML-005): a single-​arm, phase 1b and ran­do­mi­sed, phase 2 trial. DiNardo CD, Schuh AC, Stein EM, Mon­te­si­nos P, Wei AH, de Bot­ton S, Zei­dan AM, Fathi AT, Kant­ar­jian HM, Ben­nett JM, Frat­tini MG, Martin-​Regueira P, Lersch F, Gong J, Hasan M, Vyas P, Döh­ner H. Lan­cet Oncol. 2021 Nov;22(11):1597-1608. Epub 2021 Oct 18.
• Real-​world expe­ri­ence of CPX-351 as first-​line treat­ment for pati­ents with acute mye­loid leuke­mia. Rau­ten­berg C, Stöl­zel F, Röl­lig C, Stell­jes M, Gaid­zik V, Laus­eker M, Kriege O, Ver­beek M, Unglaub JM, Thol F, Krause SW, Hänel M, Neu­erburg C, Vuci­nic V, Jehn CF, Sever­mann J, Wass M, Frans­e­cky L, Chem­nitz J, Hol­tick U, Schäfer-​Eckart K, Schrö­der J, Kraus S, Krü­ger W, Kai­ser U, Scholl S, Koch K, Hen­ning L, Kobbe G, Haas R, Ala­kel N, Röh­nert MA, Sockel K, Hanoun M, Platz­be­cker U, Hol­der­ried TAW, Morg­ner A, Heu­ser M, Sauer T, Götze KS, Wagner-​Drouet E, Döh­ner K, Döh­ner H, Schlie­mann C, Sche­te­lig J, Born­häu­ser M, Ger­ming U, Schroe­der T, Mid­deke JM. Blood Can­cer J. 2021 Oct 4;11(10):164.
• Mido­stau­rin redu­ces relapse in FLT3-​mutant acute mye­loid leuke­mia: the Alli­ance CALGB 10603/RATIFY trial. Lar­son RA, Man­dre­kar SJ, Hueb­ner LJ, San­ford BL, Lau­mann K, Geyer S, Bloom­field CD, Thiede C, Prior TW, Döh­ner K, Mar­cucci G, Voso MT, Klis­ovic RB, Galin­sky I, Wei AH, Sierra J, Sanz MA, Brand­wein JM, de Witte T, Nie­der­wie­ser D, Appel­baum FR, Medei­ros BC, Tall­man MS, Krau­ter J, Schlenk RF, Gan­ser A, Serve H, Ehnin­ger G, Ama­dori S, Gath­mann I, Döh­ner H, Stone RM. Leuke­mia. 2021 Sep;35(9):2539-2551. Epub 2021 Mar 2.
• Towards pre­cision medi­cine for AML. Döh­ner H, Wei AH, Löwen­berg B. Nat Rev Clin Oncol. 2021 Sep;18(9):577-590. Epub 2021 May 18.
• A 2:1 ran­do­mi­zed, open-​label, phase II study of selin­exor vs. phy­si­cian's choice in older pati­ents with relap­sed or refrac­tory acute mye­loid leuke­mia. Sweet K, Bhat­na­gar B, Döh­ner H, Don­nellan W, Frank­furt O, Heu­ser M, Kota V, Liu H, Raf­foux E, Roboz GJ, Röl­lig C, Showel MM, Strick­land SA Jr, Vives S, Tang S, Unger TJ, Joshi A, Shen Y, Alva­rez MJ, Cali­fano A, Cro­chi­ere M, Lan­des­man Y, Kauff­man M, Shah J, Shacham S, Savona MR, Mon­te­si­nos P. Leuk Lym­phoma. 2021 Jul 29:1-12.
• Acti­vating JAK-​mutations con­fer resis­tance to FLT3 kinase inhi­bi­tors in FLT3-ITD posi­tive AML in vitro and in vivo. Rum­melt C, Gorantla SP, Meg­gen­dor­fer M, Char­let A, End­res C, Döh­ner K, Hei­del FH, Fischer T, Hafer­lach T, Duys­ter J, von Bubnoff N. Leuke­mia. 2021 Jul;35(7):2017-2029. Epub 2020 Nov 4.
• Clo­nal evo­lu­tion of acute mye­loid leuke­mia with FLT3-ITD muta­tion under treat­ment with mido­stau­rin. Schmal­b­rock LK, Dol­nik A, Coc­ci­ardi S, Sträng E, Jahn N, Panina E, Blätte TJ, Her­zig J, Skam­braks S, Rücker FG, Gaid­zik VI, Paschka P, Fied­ler W, Salih HR, Wulf G, Schroe­der T, Lüb­bert M, Schlenk RF, Thol F, Heu­ser M, Lar­son RA, Gan­ser A, Stun­nen­berg HG, Minucci S, Stone RM, Bloom­field CD, Döh­ner H, Döh­ner K*, Bul­lin­ger L.* Blood. 2021 Jun 3;137(22):3093-3104. *Equal con­tri­bu­tion.
• Post­trans­plan­ta­tion MRD moni­to­ring in pati­ents with AML by next-​generation sequen­cing using DTA and non-​DTA muta­ti­ons. Heu­ser M, Heida B, Bütt­ner K, Wie­necke CP, Teich K, Funke C, Bran­des M, Kle­ment P, Lie­bich A, Wich­mann M, Neziri B, Cha­tur­vedi A, Kloos A, Mint­zas K, Gaid­zik VI, Paschka P, Bul­lin­ger L, Fied­ler W, Heim A, Puppe W, Krau­ter J, Döh­ner K, Döh­ner H, Gan­ser A, Stad­ler M, Ham­bach L, Gab­doul­line R, Thol F. Blood Adv. 2021 May 11;5(9):2294-2304.
• Ivo­si­de­nib or ena­si­de­nib com­bi­ned with inten­sive che­mo­the­rapy in pati­ents with newly dia­gno­sed AML: a phase 1 study. Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döh­ner H, Pol­lyea DA, McClos­key J, Ode­nike O, Löwen­berg B, Ossen­kop­pele GJ, Patel PA, Roshal M, Frat­tini MG, Lersch F, Fra­no­vic A, Nab­han S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kant­ar­jian HM, Tall­man MS. Blood. 2021 Apr 1;137(13):1792-1803.
• Dere­gu­la­ted expres­sion of cir­cu­lar RNAs in acute mye­loid leuke­mia. Lux S, Blätte TJ, Gil­lis­sen B, Rich­ter A, Coc­ci­ardi S, Slam­bras S, Schwarz K, Schre­zen­meier H, Döh­ner H, Döh­ner K, Dol­nik A, Bul­lin­ger L. Blood Adv. 2021 Mar 9;5(5):1490-1503.
• Safety and effi­cacy of tala­co­tu­zu­mab plus deci­ta­bine or deci­ta­bine alone in pati­ents with acute mye­loid leuke­mia not eli­gi­ble for che­mo­the­rapy: results from a mul­ti­cen­ter, ran­do­mi­zed, phase 2/3 study. Mon­te­si­nos P, Roboz GJ, Bula­bois CE, Sub­klewe M, Platz­be­cker U, Ofran Y, Papa­yan­nidis C, Wierz­bowska A, Shin HJ, Doro­nin V, Dene­berg S, Yeh SP, Ozcan MA, Knap­per S, Cor­tes J, Pol­lyea DA, Ossen­kop­pele G, Giralt S, Döh­ner H, Heu­ser M, Xiu L, Singh I, Huang F, Lar­sen JS, Wei AH. Leuke­mia. 2021 Jan;35(1):62-74.